Cabaletta Bio’s Post

Calling all #lupus specialists & researchers: The April edition of our Literature Highlights & detailed slide decks are now available on the Lupus-Forum, featuring key advancements in lupus research and therapeutics. This month, we delve into topics such as the safety and efficacy of CD19 #CAR-T cell therapy, the role of #anifrolumab in treating #SLE, the establishment of autoantigen-specific Treg-cell-based therapy in #LN, and the latest on cardiovascular risk factors in #SLE patients: https://lnkd.in/dCk9aBNk

Biotech communications professionals often use terms like paradigm shifting, best-in-class, novel, etc. I’m guilty of it too. But the topline results presented today are more than just a subjective interpretation of data. Despite a relatively small study, the MG patients that responded to Descartes-08 did so with disease modifying results. This treatment didn’t just manage their symptoms – it altered how they were able to live.   Proud to be part of Cartesian Therapeutics, looking forward to advancing Descartes-08 for #myastheniagravis to a phase 3 trial, and seeing the future potential of our platform for #autoimmunity.

Safety, Efficacy and Cellular Kinetics of YTB323, a Rapid Manufacturing CAR-T Cell Therapy Targeting CD19 on B Cells, for Severe Refractory Systemic Lupus Erythematosus Preliminary data from this clinical trial including the first three sentinel patients suggest favorable safety, CAR-T cell expansion, B cell depletion and initial efficacy, supporting continuation of the study to evaluate YTB323 in srSLE.

Significant progress has been achieved in the realm of therapeutic interventions for multiple myeloma (MM), leading to transformative shifts in its clinical management. This article provides an overview of CAR-T cell therapy in Multiple Myeloma (MM), the utilization of B-cell maturation antigen (BCMA) as the target antigen, and an overview of other target moieties. https://lnkd.in/gsEejDfc

Early results presented at #ESMOAsia23 show that the selective inhibitor nanatinostat is well tolerated in patients with recurrent/metastatic EBV-positive nasopharyngeal carcinoma and shows evidence of antitumour activity when used in combination with antiviral therapy. To learn more about this topic, read the article on #ESMODailyReporter https://ow.ly/xxnu50QeG7J

Today marks an important milestone for Cartesian as we share positive topline results from our Phase 2b trial of Descartes-08 in patients with #myastheniagravis. Descartes-08 is the first mRNA cell therapy designed to treat MG. Learn more about the results and next steps as we continue our journey to treat #autoimmunediseases: https://bit.ly/3xJjvXA

The mechanisms underlying #enhanced #immunotherapy efficacy through #exercise. (A) The #antitumor effects of exercise depend on IL-15 signaling pathway, thus enhancing the sensitivity of pancreatic tumor cells to immunotherapy. (B) Exercise increases the infiltration of CD8+ T cells through the CXCL9 or CXCL11/CXCR3 signaling pathway. (C) Exercise influences multiple transcriptional pathways, including promotion of vascular branching and normal vasoconstriction, which improves hypoxia in TME and enhances the efficiency of drug transport.

Join this exciting webinar hosted by Ellegaard Göttingen Minipigs, who have invited a scientist to share his knowledge on "Heart Ventricular Progenitor Cell Therapy and Using Göttingen Minipigs for Development of Curative Cardiovascular Cell Therapies". #EllegaardBioresearch #GöttingenMinipigs #GöttingenMinipigsAcademy

Starting with nivolumab and then adding ipilimumab later on does not appear to be as effective as giving ipi/nivo up front, but is more effective than giving nivolumab alone, according to this phase II trial in renal cell carcinoma.  We know ipi/nivo can be very difficult for patients to tolerate due to its side effect profile, but this trial appears to definitively prove that escalating therapy is less effective than giving dual checkpoint inhibitor upfront. Unfortunately, there does not seem to be any way to ease a patient into dual checkpoint inhibition, you just have to give it to them and hope for the best. #opdivo #yervoy #kidneycancer https://lnkd.in/dAwi8HgF

For most patients with ER+, HER2- #MetastaticBreastCancer (MBC), endocrine therapy is the therapeutic backbone throughout their treatment journey and used frequently in regimen combinations. Endocrine therapies target the estrogen receptor pathway, either by blocking receptor binding using an antagonist or by depriving the tumor of estrogen. Click here to discover endocrine therapies that target the estrogen receptor pathway in MBC: https://e.lilly/3Sukz8G #BreastCancer #BCSM #MBC